ライフサイエンスコーパス: tail vein injection

1 ng in vivo bioluminescence imaging following tail vein injection.

2 livers of outbred ICR mice via hydrodynamic tail vein injection.

3 in the lung after systemic administration by tail vein injection.

4 . actinomycetemcomitans were transferred via tail vein injection.

5 HBV vector were codelivered via high-volume tail vein injection.

6 essed formation of lung metastases following tail vein injection.

7 ses of more aggressive carcinoma cells after tail vein injection.

8 line reduces colonization of the lungs in a tail vein injection.

9 to the livers of mice by using high-pressure tail vein injection.

10 pes simplex virus type 1-specific T cells by tail vein injection.

11 , such a high expression was not found after tail vein injection.

12 ion of the liver or by systemic delivery via tail vein injection.

13 with resting Aspergillus conidia via lateral tail vein injection.

14 e C57BL/6 mice at multiple time points after tail vein injection.

15 were introduced into syngeneic hosts through tail vein injection.

16 model generated by means of subcutaneous or tail vein injection.

17 duced AOP1 expression in the whole brain via tail vein injection.

18 etVLDL) was administered to mice by means of tail vein injection.

19 ar, and colonize mouse lung tissue following tail vein injection.

20 ell transduction, stereotactic injection, or tail vein injection.

21 HepG2 colonization into lung and liver after tail vein injection.

22 by administering an insulin stimulation via tail vein injection.

23 ration of 42.1 +/- 3.9 MBq of (18)F-FMISO by tail vein injection.

24 tively transferred to recipient mice through tail vein injection.

25 ells to colonize the lung when delivered via tail vein injection.

26 and administered to healthy mice by lateral tail vein injection.

27 ng proved fast clearance of the tracer after tail vein injection.

28 accumulation of M2pep in TAMs in vivo after tail vein injection.

29 , or phosphate buffered saline (PBS) through tail vein injection.

30 from anesthesia when administered to mice by tail vein injection.

31 pic reinjection and of lung metastases after tail vein injection.

32 showed increased pulmonary tumor growth upon tail vein injection.

33 idiasis with C. albicans A72 administered by tail vein injection.

34 d 1 hr after initiation of sepsis via single tail-vein injection.

35 a 500 kBq/kg dose of (227)Th-octapa-aGPC3 by tail-vein injection.

36 0 kBq/kg dose of (227)Th-octapa-alphaGPC3 by tail-vein injection.

37 ility form lung metastases in mice following tail-vein injection.

38 le to form pulmonary tumor nodules following tail-vein injection.

39 cally investigated using intraperitoneal and tail-vein injection.

40 at the time of liver injury via hydrodynamic tail-vein injection.

41 aluated AAV8 against AAV2 in intraportal and tail vein injections.

42 ificantly larger effects in both organs than tail vein injections.

43 NS alphaS pathology in M83 mice than i.p. or tail vein injections.

44 ey rats (n = 36) were studied at 9.4 T after tail vein injections.

45 lung cancer cell dissemination in mice after tail vein injections.

46 hydrolase (Fah) mutant mice via hydrodynamic tail vein injections.

47 e-matched, irradiated LH(BETA)T(AG) mice via tail vein injections.

48 xpressed in the mouse liver via hydrodynamic tail-vein injections.

49 yte number in living mice was assessed after tail vein injection (150 mug of each conjugate per mouse

50 ither p16 or control Vivo Morpholino (VM) by tail vein injection 2x during the 16th week of feeding.

51 Following lateral tail vein injection, 3T3 cells transformed by constituti

52 4 (Pc 4), was delivered to each animal by a tail vein injection 48 h before laser illumination.

53 of HCC tumors induced using the hydrodynamic tail vein injection and orthotopic implantation models i

54 he number of metastatic nodules in mice with tail vein injection and orthotopic implantation.

55 ation and inhibits metastasis to lung in the tail-vein injection and the oral cavity xenograft models

56 nomas were treated with 10 mg/kg of 5-Se via tail-vein injection and with 720 J cm(-2) of 570-750-nm

57 he vector was administered into nude mice by tail vein injection, and exogenous creatine was administ

58 ice were infected with MUP1 adenoviruses via tail vein injection, and recombinant MUP1 was overexpres

59 ide phosphate (L-BudP) were administered via tail vein injection, and the feasibility of L-BudP to re

60 In the subcutaneous xenograft and tail vein injection assays, these cells had significantl

61 re retained in the murine lung 6 h following tail vein injection; coexpression of EDG2 enhanced reten

62 tumor cell extravasation into the lung after tail vein injection compared with tumors expressing wild

63 n of RGS7 via introduction of RGS7 shRNA via tail vein injection decreased doxorubicin-induced hepati

64 ry of radiotracers remains a challenge, with tail vein injections demonstrated to be technically diff

65 NAs delivered to mouse liver by hydrodynamic tail vein injection edited reporter constructs at rates

66 KP2a was delivered to adult mice by a single tail vein injection either before or after tamoxifen-act

67 substantially inhibited lung colonization in tail vein injection experiments in immunodeficient mice.

68 In mouse tail-vein injection experiments, a construct containing

69 Following tail vein injection, fluorescence arising from dye-conju

70 ty of approximately 12 MBq (64)Cu-GPVI-Fc by tail vein injection followed by delayed (24 hours) posit

71 promoter fragments was confirmed in vivo by tail vein injection followed by luciferase reporter assa

72 ted with mismatch or H2HR vivo-morpholino by tail vein injection for 1 week.

73 pharmacokinetic data equivalent to data from tail-vein injection for small-animal (18)F-FDG PET.

74 by adeno-associated viral vector via single tail vein injection immediately following induction of M

75 ), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model.

76 the blood-brain barrier, to access brain via tail vein injection in mice.

77 ting capsids by direct in vivo panning after tail vein injection in mice.

78 n immunoliposomes to the mesangium following tail vein injection in mice.

79 merulus and glomerular mesangial cells after tail vein injection in normal and nephritic mice.

80 el and that DN-PPARgamma ECV304 cells, after tail vein injection in nude mice, form lumen-obliteratin

81 imental lung metastasis model established by tail vein injection in severe combined immunodeficient m

82 and metastasis in vitro and in cells before tail vein injection in vivo.

83 ively validate the top-ranked peptides using tail vein injections in breast, myeloma and lung tumour

84 nvasion and formation of lung colonies after tail-vein injection in SCID mice.

85 In addition, tail-vein injections in mice with human breast cancer MC

86 ous CIK cells were injected intravenously by tail vein injection into groups of mice, and the animals

87 )-labeled Abeta42 and Abeta40 introduced via tail vein injection into mice with a BBB rendered permea

88 Following tail vein injection into rats, (M6P)(20)-BSA-(33)P-TFO r

89 ferase-positive splenocytes, transferred via tail vein injection into the brains of HSV-infected anim

90 enhancer, was delivered through hydrodynamic tail vein injection into VWF knockout mice (VWF(-/-)) th

91 as surrounding omega1-mutated eggs following tail-vein injection into mice was vastly reduced.

92 mine or polyethyleneimine alone (placebo) by tail-vein injection into nude mice with prostate and bre

93 s(-1) and arrested in the lungs 2-3 s after tail-vein injection into the mice, which is consistent w

94 mic administration of siMGMT-SNAs via single tail vein injection is capable of robust intratumoral MG

95 In a tail-vein injection metastatic model, Frzb-transfected H

96 in vivo BALB/c nude mice xenograft model and tail vein injection model showed that berberine treatmen

97 ased replication assay with the hydrodynamic tail vein injection model to investigate the function(s)

98 indered metastasis in vitro and in vivo in a tail vein injection model.

99 ion in vitro and lung metastasis burden in a tail-vein injection model in comparing isogenic cells (s

100 model and reduced pulmonary metastases in a tail-vein injection model in vivo .

101 models and enhanced lung tumor metastasis in tail-vein injection models.

102 KDC1 was prometastatic in HCC orthotopic and tail vein injection mouse models.

103 with ketamine/xylazine and catheterized for tail vein injection of (11)C-raclopride.

104 RLT was performed by administering a single tail vein injection of (177)Lu-PSMA-617 at different for

105 s performed in wild-type rats at 1 hour post tail vein injection of (64)Cu-DOTA-ECL1i.

106 omized into subgroups that received either a tail vein injection of 3 x 10 orbital fat-derived stem/s

107 ution studies were done in male CD-1 mice by tail vein injection of 3.7 MBq (100 microCi) of the (11)

108 One and 2 h after tail vein injection of 30 x 10(6) ex vivo (18)F-FDG-labe

109 by counting tumor cells in lung at 6 h after tail vein injection of a mixture of fluorescently tagged

110 When SIRT4 was knocked down in vivo by tail vein injection of a shRNA adenovirus, we observed a

111 Tail vein injection of a standard Ad5-based vector into

112 rmed in an animal model of lung cancer using tail vein injection of A549 cells in SCID mice.

113 In adult mice, tail vein injection of AAV9-GFP leads to robust transduc

114 Tail vein injection of adenovirus expressing the HNF6 co

115 mice developmentally (LivARKO) or acutely by tail vein injection of an adeno-associated virus with a

116 Finally, tail vein injection of an M2pep fusion peptide with a pr

117 A tail vein injection of anti-DLK1 Ab at 6 h after PH redu

118 PET data were acquired after tail vein injection of approximately 9 MBq of (18)F-FPAC

119 atic lung melanoma tumour-bearing mice after tail vein injection of both treatments, suggesting that

120 arrying s.c. LNCaP xenografts, a single i.v. tail vein injection of CV787 eliminates 300-mm3 tumors w

121 Tail vein injection of human endothelial specific Ulex e

122 lity of ultrafast multislice (13)C MRI after tail vein injection of hyperpolarized (13)C-phospholacta

123 Furthermore, tail vein injection of miR-223 lentiviral vector to miR-

124 to 4, microPET images were obtained after a tail vein injection of nitrogen-13 ammonia ([13N]-NH3) a

125 bserved in mouse CCA induced by hydrodynamic tail vein injection of notch intracellular domain (NICD)

126 a mouse model of CCA induced by hydrodynamic tail vein injection of Notch1 intracellular domain and m

127 Following tail vein injection of OS cells into mice, both molecule

128 etent mice with HCC, induced by hydrodynamic tail vein injection of proto-oncogenes, enhanced HCC dev

129 s of ocular and brain tissues after a single tail vein injection of SVV-001 (1 x 10(13) vp/kg) showed

130 A single tail vein injection of the rAAV8 vector was as efficient

131 njected dose per gram (%ID/g) 72 hours after tail vein injection of the radiolabeled probe in subcuta

132 the number of lung metastases 14 days after tail vein injection of tumor cells, with alveolar wall i

133 bserved in a VEGF-dependent manner following tail vein injection of tumor cells.

134 BL/6J mice were randomly assigned to receive tail vein injections of 1 mug/kg of remifentanil or norm

135 or TBI dose level per experiment were given tail vein injections of 100 microg of (131)I-labeled 30F

136 Some mice were given tail vein injections of a vector encoding a secreted for

137 In this study, we show that mouse tail vein injections of adenovirus expressing the rat HN

138 In tail vein injections of alternative cancer models, bicar

139 Mice were given hydrodynamic tail vein injections of clustered regularly interspaced

140 ks; select WT and Kit(W-sh) WD mice received tail vein injections of MCs 2 times per week for 2 weeks

141 Tail vein injections of Sod2-GFP-expressing HT-1080 cell

142 ter implantation only (n = 99); 176 received tail vein injections of Staphylococcus epidermidis on po

143 the approach in mice, C57BL/6 mice received tail vein injections of two vectors, AAV8-SaCas9-gRNA, t

144 ost-myocardial infarction were randomized to tail-vein injection of 2x10(6) MSCs, with injection repe

145 MIR122 was inhibited in mice by tail-vein injection of an oligonucleotide antagonist of

146 Tail-vein injection of B16-F10 cells that stably express

147 tal metastasis assay we detail here includes tail-vein injection of cancer cells into the mouse and d

148 Orthotopic reinjection and tail-vein injection of cells arising from tumors, couple

149 ing, CCl4 is administered for 12 weeks after tail-vein injection of Cre-expressing adenovirus (adeno-

150 Hydrodynamic tail-vein injection of MAN2A1-FER resulted in rapid deve

151 more, after 6 weeks of bi-weekly intravenous tail-vein injection of miR1 mimics, the ejection fractio

152 ouse model of tyrosinaemia that hydrodynamic tail-vein injection of plasmid DNA encoding the adenine

153 Other groups received a tail-vein injection of serum from either HDM-sensitized

154 cell lines and for metastasis as assessed by tail-vein injection of three different tumorigenic cell

155 ice with hepatic deletion of PTEN were given tail-vein injections of MAN2A1-FER.

156 Mice were given 1 or 2 tail-vein injections of TIMP-GLIA or control nanoparticl

157 tinal (GI) tumors in immunodeficient mice by tail-vein injection rather than surgery.

158 and lung colonization after subcutaneous and tail vein injections, respectively.

159 of Cre-recombinase in ILK-floxed animals by tail vein injection resulted in acute hepatitis, with a

160 earing B16/F10 and A375M tumors at 1 h after tail vein injection revealed good B16/F10 tumor-to-backg

161 butions of the nanoparticles 24 h after i.v. tail-vein injections show that the nanoparticle accumula

162 er a functional human ABCC6 via hydrodynamic tail vein injection to approximately 13% of mouse hepato

163 ntibody (Ab; DOTA-30F11) was administered by tail vein injection to athymic mice bearing disseminated

164 CC, or control Cas9 vector, via hydrodynamic tail vein injection to livers of 8-week-old female FVB/N

165 ICAM-1 blocking antibody was administered by tail vein injection to mice following thoracic irradiati

166 toris (phLAL), purified, and administered by tail vein injections to lal( -/-) mice.

167 ioned with carbon monoxide were delivered by tail vein injections to septic mice.

168 ransposon, delivered as naked plasmid DNA by tail-vein injection, to integrate B-domain-deleted FVIII

169 was administered to Sprague-Dawley rats via tail vein injection using the carrier polyethylenimine.

170 pecific gene transfer following hydrodynamic tail vein injection using the kidney-specific podocin an

171 Metastasis to the lung via tail vein injection was reduced in the 4T1-WNT5A express

172 e for liver transplantation models with MRSA tail vein injection, we demonstrated that Panx1 deficien

173 By performing hydrodynamic tail-vein injections, we tested the impact of altering a

174 es for (18)F-FPA and (14)C-acetate 1 h after tail vein injection were 7.08 +/- 0.80 and 0.36 +/- 0.08

175 of these cells to form lung metastases after tail-vein injection, whereas mTerc reconstitution alone

176 BALB/c mice were infected by tail vein injection with 2 x 10(5) organisms of wild typ

177 he rAAV FIX genome in liver and spleen after tail vein injection with a higher proportion in liver af

178 nockout (CD18-ko) and wild-type (WT) mice by tail vein injection with Listeria.

179 ly divided to six groups and received weekly tail vein injection with PBS, EGCG, void nanoparticles (

180 Male BALB/c mice were infected via tail vein injection with wild-type C. albicans or with a

181 evels during BDL liver injury, we used mouse tail vein injections with recombinant adenovirus express

182 s of CN-105 (0.05 mg/kg) was administered by tail vein injection within 24 hours after ICH induction.

183 asis from orthotopic primaries and following tail vein injection without further VEGF treatment.

184 on in vitro and increases metastases in both tail-vein injection xenografts and LUAD patient-derived